Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01211808 | Effect of Diltiazem on Pharmacokinetics of BMS-914392 | PHASE1 | COMPLETED | 24 | — | — | Sep 1, 2010 | Oct 1, 2010 | Feb 2, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment A (BMS-914832) | EXPERIMENTAL | - |
| Treatment B (BMS-914832 + diltiazem) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-914832 | DRUG | Tablets, Oral, 30 mg, once, 1 day |
| Diltiazem | DRUG | Tablets, Oral, 360 mg, once daily, 10 days |
Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avo...